Ropivacaine Hydrochloride

-- Issues Statement in Response to DOMA’s Nomination of Director Candidates -- -- No Shareholder Action Required at This Time -- BRISBANE, Calif., March 11, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today confirmed that DOMA Perpetual Capital Management LLC (“DOMA”) has nominated three director candidates to stand for election to the Pacira Board of Directors (the “Board”) at the Company’s 2026 Annual Meeting of Stockholders (the “2026 Annual Meeting”). Pacira’s Board issued the following statement: The Pacira Board of Directors and management team are committed to serving the best interests of the Company and all its shareholders. In January 2025, we launched our 5x30 strategy, a focused five-pillar plan with clear, measurable objectives we intend to achieve by 2030 to accelerate performance and position us for sustainable long-term value creation. Today, we are pleased to reiterate the significant progress we have made against these goals in just over a year, including: Treated 2.5 million patients with our products in 2025, reinforcing our path to help 3 million patients annually by 2030. Increased EXPAREL® (bupivacaine liposome injectable suspension) year-over-year volume growth to 6.2% in 2025 versus 3.6% in 2024, marking tangible progress toward our goal of double-digit compounded annual topline growth. We further reinforced our 5-year revenue goal with key intellectual property milestones, namely: Secured a favorable volume-limited settlement of our multi-year patent infringement lawsuit. Strengthened our intellectual property estate to 21 Orange-Book listed patents across two families protecting the EXPAREL franchise, a dramatic evolution from the single patent that was previously litigated. Achieved record-high 2025 GAAP and non-GAAP gross margins of 79% and 81%, respectively, and are on track for our goal of a five-percentage point gross margin improvement over a 2024 baseline of 76%. Advanced two promising Phase 2 clinical programs, PCRX-201 (enekinragene inzadenovec), our novel locally administered gene therapy for osteoarthritis (OA), and PCRX-2002, our complementary, ropivacaine-based, long-acting local analgesic for postsurgical pain. We are now entering a data-rich period with key 2026 milestones that include (i) an interim analysis from our Phase 3 study of ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) in shoulder OA, (ii) topline results from our iovera registration study for the treatment of spasticity, and (iii) 52-week data from Part A of our Phase 2 study of PCRX-201 in knee OA. Expanded our commercial reach both inside and outside the U.S. by signing high-caliber commercial collaborations with J&J MedTech and LG Chem. In our regular conversations with Pacira shareholders representing a majority of outstanding shares, we have heard clear support for our growth strategy. With that, we are accelerating our transition into an innovative biopharmaceutical and therapeutic leader in musculoskeletal pain and adjacencies all while advancing a discipline capital allocation strategy that includes (i) driving topline growth by leveraging our established commercial infrastructure; (ii) advancing an innovative pipeline; and (iii) returning capital to shareholders. In 2025, we executed $150 million in common stock repurchases, reducing our outstanding shares from 47 to 41 million. Since Frank Lee became Pacira’s Chief Executive Officer in January of 2024, members of our Board and leadership team have met with DOMA 12 times. DOMA has not provided any new insights regarding our strategy or operations that the Company and the Board are not already carefully evaluating and executing as part of our 5x30 strategy for growth and value creation. The Pacira Board and management team will continue to act in the best interests of the Company and all its shareholders and remain confident that Pacira is well positioned to accelerate growth and continue executing its long-term plan to deliver value. The Board’s Nominating, Governance and Sustainability Committee will carefully review the proposed nominees in due course, consistent with its established processes and corporate governance guidelines. The Board will present its recommendation with respect to the election of directors in the Company’s definitive proxy statement, which will be filed with the U.S. Securities and Exchange Commission and distributed to all shareholders eligible to vote at the 2026 Annual Meeting. The date of the Annual Meeting has not yet been announced, and shareholders are not required to take any action at this time. About Pacira Pacira BioSciences delivers innovative, non-opioid pain therapies to transform the lives of patients. Pacira has three commercial-stage non-opioid treatments: EXPAREL® (bupivacaine liposome injectable suspension), a long-acting local analgesic currently approved for infiltration, fascial plane block, interscalene brachial plexus nerve block in adults, sciatic nerve block in the popliteal fossa in adults, and adductor canal block in adults for postsurgical pain management; ZILRETTA® (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular injection indicated for the management of osteoarthritis knee pain; and iovera ® °, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. The company is also advancing a pipeline of clinical-stage assets for musculoskeletal pain and adjacencies, its most advanced product candidate, PCRX-201 (enekinragene inzadenovec), a novel locally administered gene therapy in Phase 2 clinical development for osteoarthritis of the knee To learn more about Pacira, visit Forward-Looking Statements Any statements in this document about Pacira’s future expectations, plans, trends, outlook, projections and prospects, and other statements containing the words “believes,” “anticipates,” “plans,” “estimates,” “expects,” “intends,” “may,” “will,” “would,” “could,” “can” and similar expressions, constitute forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the Private Securities Litigation Reform Act of 1995, including, without limitation, statements related to: the 2026 annual meeting of shareholders; Pacira’s board of directors, the contributions of new directors; ‘5x30’, our growth and business strategy, our future outlook, the strength and efficacy of our intellectual property protection and patent terms, our future growth potential and future financial and operating results and trends, our plans, objectives, expectations (financial or otherwise) and intentions, including our plans with respect to the repayment of our indebtedness, anticipated product portfolio and product development programs, strategic alliances, plans with respect to the Non-Opioids Prevent Addiction in the Nation (“NOPAIN”) Act and any other statements that are not historical facts. For this purpose, any statement that is not a statement of historical fact should be considered a forward-looking statement. We cannot assure you that our estimates, assumptions and expectations will prove to have been correct. Actual results may differ materially from these indicated by such forward-looking statements as a result of various important factors, including risks relating to, among others: risks associated with acquisitions, such as the risk that the acquired businesses and/or assets will not be integrated successfully, that such integration may be more difficult, time-consuming or costly than expected or that the expected benefits of the transaction will not occur; our manufacturing and supply chain, global and United States economic conditions (including tariffs, inflation and rising interest rates), and our business, including our revenues, financial condition, cash flows and results of operations; the success of our sales and manufacturing efforts in support of the commercialization of EXPAREL ® (bupivacaine liposome injectable suspension), ZILRETTA ® (triamcinolone acetonide extended-release injectable suspension) and iovera ® °; the rate and degree of market acceptance of EXPAREL, ZILRETTA and iovera°; the size and growth of the potential markets for EXPAREL, ZILRETTA and iovera° and our ability to serve those markets; our plans to expand the use of EXPAREL, ZILRETTA and iovera° to additional indications and opportunities, and the timing and success of any related clinical trials for EXPAREL, ZILRETTA, iovera° and any of our other product candidates, including but not limited to PCRX-201 (enekinragene inzadenovec); the commercial success of EXPAREL, ZILRETTA and iovera°; the related timing and success of United States Food and Drug Administration supplemental New Drug Applications and premarket notification 510(k)s; the related timing and success of European Medicines Agency Marketing Authorization Applications; our plans to evaluate, develop and pursue additional product candidates utilizing our proprietary multivesicular liposome (“pMVL”) drug delivery technology or our proprietary high-capacity adenovirus (“HCAd”) vector platform; the approval of the commercialization of our products in other jurisdictions (by either us or our partners); clinical trials in support of an existing or potential pMVL- or HCAd-based product; our commercialization and marketing capabilities; our ability to successfully complete capital projects; the outcome of any litigation; the recoverability of our deferred tax assets; assumptions associated with contingent consideration payments; assumptions used for estimated future cash flows associated with determining the fair value of the company; the anticipated funding or benefits of our share repurchase program; and factors discussed in the “Risk Factors” of Pacira’s most recent Annual Report on Form 10-K and in other filings that it periodically makes with the SEC. In addition, the forward-looking statements included in this document represent Pacira’s views as of the date of this document. Important factors could cause actual results to differ materially from those indicated or implied by forward-looking statements, and as such Pacira anticipates that subsequent events and developments will cause its views to change. Except as required by applicable law, Pacira undertakes no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, and readers should not rely on these forward-looking statements as representing Pacira’s views as of any date subsequent to the date of this document. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Pacira’s actual results, levels of activity, performance or achievements to differ materially from those expressed or implied by these statements. These factors include the matters discussed and referenced in the “Risk Factors” of Pacira’s most recent Annual Report on Form 10-K and in other filings that Pacira periodically makes with the SEC. Important Additional Information Regarding Proxy Solicitation Pacira intends to proxy statement and BLUE proxy card with the U.S. Securities and Exchange Commission (the “SEC”) in connection with its solicitation of proxies for Pacira’s 2026 annual meeting of stockholders (the “2026 Proxy Statement,” and such meeting the “2026 Annual Meeting”). BEFORE MAKING ANY VOTING DECISION, INVESTORS AND STOCKHOLDERS OF PACIRA ARE URGED TO READ ALL RELEVANT DOCUMENTS FILED WITH OR FURNISHED TO THE SEC, INCLUDING PACIRA’S DEFINITIVE PROXY STATEMENT AND ANY AMENDMENTS AND SUPPLEMENTS THERETO, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. These documents, including the definitive 2026 Proxy Statement (and any amendments or supplements thereto) and other documents filed by Pacira with the SEC, are, or will be when available for no charge on the SEC’s website at and on Pacira’s investor relations website at Participants in the Solicitation Pacira, its directors, director nominees, certain of its executive officers and other employees may be deemed participants in the solicitation of proxies from stockholders in respect of the 2026 Annual Meeting. Information regarding the names of Pacira’s directors and executive officers and their respective interests in Pacira by security holdings or otherwise is set forth in Pacira’s proxy statement for the 2025 Annual Meeting of stockholders, filed with the SEC on April 29, 2025 (the “2025 Proxy Statement”). Please refer to the sections captioned “Director Compensation,” “Executive Compensation,” and “Stock Ownership Information” in the 2025 Proxy Statement. To the extent holdings of such participants in Pacira’s securities have changed since the amounts described in the 2025 Proxy Statement, such changes have been reflected on Initial Statements of Beneficial Ownership of Securities on Form 3 or Statements of Changes in Beneficial Ownership of Securities on Form 4 filed with the SEC: Form 4, filed by Jonathan Slonin on June 5, 202 5 ; Form 4, filed by Kristen Williams on June 5, 202 5 ; Form 4, filed by Lauren Riker on June 5, 202 5 ; Form 4, filed by Alethia Young on June 13, 202 5 ; Form 4, filed by Michael J. Yang on June 13, 202 5 ; Form 4, filed by Laura Brege on June 1 3 , 202 5 ; Form 4, filed by Christopher Christie on June 13, 202 5 ; Form 4, filed by Mark Froimson on June 13, 202 5 ; Form 4, filed by Marcelo Bigal on June 13, 2025 ; Form 4, filed by Abraham Ceesay on June 13, 202 5 ; Form 4, filed by Mark A. Kronenfeld on June 13, 202 5 ; Form 4, filed by Jonathan Slonin on August 4 , 202 5 ; Form 4, filed by Marcelo Bigal on August 1 1 , 202 5 ; Form 4, filed by Abraham Ceesay on September 8, 2025 , Form 4, filed by Shawn Cross on November 3, 202 5 ; Form 4, filed by Shawn Cross on November 1 3, 202 5 ; Form 4, filed by Jonathan Slonin on November 1 9 , 202 5 ; Form 4, filed by Shawn Cross on December 11, 2025 ; Form 4, filed by Frank Lee on J anuary 6, 2026 ; Form 4, filed by Jonathan Slonin on January 6, 2026 ; Form 4, filed by Brendan Teehan on January 6, 2026 ; Form 4 filed by Lauren Riker on Januar y 6, 2026 ; Form 3, filed by Samit Hirawat on January 29, 2026 ; Form 4, filed by Samit Hirawat on January 2 9, 2026 ; Form 4, filed by Lauren Riker on Feb ruary 3, 2026 ; Form 4, filed by Kristen Williams on February 3, 2026 ; Form 4, filed by Jonathan Slonin on February 3, 2026 ; Form 4, filed by Brendan Teehan on February 3, 2026 ; Form 4, filed by Frank Lee on February 3, 2026 ; Form 4, filed by Kristen Williams on February 13, 2026 ; Form 4, filed by Shawn Cross on February 13, 2026 ; Form 4, filed by Jonathan Slonin on February 13, 2026 ; Form 4, filed by Frank Lee on February 13, 2026 ; Form 4, filed by Brendan Teehan on February 13, 2026 ; Form 4 filed by Lauren Riker on Feb ruary 13, 2026 . Additional information can also be found in Pacira’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on February 26, 2026 . Details concerning potential participants in the solicitation, including Pacira’s director nominees for election at the 2026 Annual Meeting, will also be included in the 2026 Proxy Statement. These documents, including the definitive 2026 Proxy Statement (and any amendments or supplements thereto) and other documents filed by Pacira with the SEC, are, or will be when available for no charge on the SEC’s website at and on Pacira’s investor relations website at Non-GAAP Financial Information This document contains a financial measure that does not comply with U.S. generally accepted accounting principles (GAAP), non-GAAP gross margin, because this non-GAAP financial measure excludes the impact of items that management believes affect comparability or underlying business trends. This measure supplements Pacira’s financial results prepared in accordance with GAAP. Pacira management uses this measure to better analyze its financial results, estimate its future gross margin and to help make managerial decisions. In management’s opinion, this non-GAAP measure is useful to investors and other users of Pacira’s financial statements by providing greater transparency into the ongoing operating performance of Pacira and its future outlook. Such measure should not be deemed to be an alternative to GAAP requirements. The non-GAAP measure presented here is also unlikely to be comparable with non-GAAP disclosures released by other companies. See the table below for a reconciliation of GAAP gross margin to non-GAAP gross margin. Pacira BioSciences, Inc. Reconciliation of GAAP to Non-GAAP Financial Information (in thousands, except percentages) (unaudited) Year Ended December 31, 2025 2024 Gross margin reconciliation: GAAP total revenues $ 726,411 $ 700,966 GAAP gross margin $ 576,662 $ 530,538 GAAP gross margin percentage 79 % 76 % Adjustments to GAAP gross margin: Stock-based compensation $ 6,448 $ 5,331 Decommissioning of manufacturing suite 1 6,521 — Non-GAAP gross margin $ 589,631 $ 535,869 Non-GAAP gross margin percentage 81 % 76 % [1] In July 2025, as a result of improving manufacturing efficiencies for EXPAREL, we announced the decommissioning of our 45-liter EXPAREL batch manufacturing suite located at our Science Center Campus in San Diego, California, and reduced our workforce accordingly. During the year ended December 31, 2025, we recognized $6.5 million of accelerated depreciation expense on fixed assets and reserved raw materials associated with this manufacturing suite that was recorded to cost of goods sold in the consolidated statement of operations. Contacts Investor Contact Susan Mesco (973) 451-4030 susan.mesco@pacira.com Media Contact Sara Marino (973) 370-5430 sara.marino@pacira.com

-- Studies highlight the clinical effectiveness of EXPAREL for total knee arthroplasty and long-term pain management with iovera º for patients with osteoarthritis (OA) of the knee -- -- Data presented at the American Academy of Orthopedic Surgeons 2026 Annual Meeting -- BRISBANE, Calif., March 02, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today presented real-world evidence from its Innovations in Genicular Outcomes Registry, (IGOR), a first-of-its-kind multicenter, prospective, longitudinal observational registry. The first study demonstrated that EXPAREL® (bupivacaine liposome injectable suspension) was associated with improvements in pain, opioid use, function, and length of stay after receiving EXPAREL following total knee arthroplasty (TKA) as compared to patients who received conventional bupivacaine and ropivacaine. The second study demonstrated that cryoneurolysis treatment with ioveraº was associated with longer-term improvement in pain and function for up to 12 months, relative to a typical improvement of outcomes for 4-6 months following alternative intra-articular agents. The data were presented at the American Academy of Orthopedic Surgeons (AAOS) 2026 Annual Meeting taking place March 2-6 in New Orleans, Louisiana. “OA is a unique condition that patients live with for decades and receive a myriad of pain treatments as their disease progresses. The IGOR is providing much-needed real-world evidence and in-depth insights into the patient journey, including the relationship between pain, opioid use, and recovery outcomes,” said Jonathan Slonin, Chief Medical Officer at Pacira. “The data being generated from this first-of-its-kind registry have the potential to meaningfully inform evidence-based preoperative pain management strategies and optimize postoperative recovery outcomes for patients with OA knee pain.” Pacira Presentations at AAOS 2026: “Intraoperative Liposomal Bupivacaine Is Associated With Improved Pain, Opioid Use, Functional, and Length of Stay Outcomes After Total Knee Arthroplasty: Real-world Evidence” (Poster #e0234): Evaluates the real-world effectiveness of liposomal bupivacaine (LB) versus conventional local anesthetics (LAs) in patients undergoing primary total knee arthroplasty (TKA). Data was collected from IGOR for opioid-naive patients who underwent unilateral primary TKA with up to 3 months of follow-up after surgery (LB, n=42; conventional LAs, n=183). The numerical rating scale (NRS) was used to assess acute pain during the first postsurgical week, and the Brief Pain Inventory-Short Form (BPI-SF) was used to assess chronic pain for subsequent time points. The data showed that patients receiving LB demonstrated lower average and worst pain scores (as measured by NRS) than those receiving conventional LAs in the first 5 days (average pain, 3.9 vs 4.9 [ P <0.001]; worst pain, 5.9 vs 7.1 [ P <0.001]) as well as lower average pain scores measured by BPI-SF scores in the subsequent 3 months (2.6 vs 2.9; P =0.03) after TKA. Worst pain scores within the first 5 days were also lower among patients receiving LB compared with those receiving conventional LAs ( P <0.001). Additionally, patients who received LB were also discharged earlier than those receiving conventional LAs (15.0 vs 20.6 h; P=0.007). Presenter : Mary DiGiorgi, Senior Vice President, Clinical Development & Clinical Affairs, Pacira BioSciences Poster Number : e0234 Date & Time : March 2 n d , 2026, 7:00 AM CST “Cryoneurolysis for Knee Osteoarthritis in a Real-World Registry: Pain and Functional Outcomes over 12 Months” (Poster #e0233): Evaluates real-world pain and functional outcomes from the Innovations in Genicular Outcomes Registry (IGOR) following cryoneurolysis therapy for knee osteoarthritis (OA). In this prospective, observational, registry-based real-world study, two cryoneurolysis approaches were evaluated in adult patients with primary knee OA. Data on pain and functional outcomes were collected from IGOR for up to 12 months of follow-up after cryoneurolysis treatment (of 129 patients who received cryoneurolysis, 75 received Cryo-Deep/Both and 54 received Cryo-Superficial). The data presented signifies that treatment with cryoneurolysis in patients with knee OA was associated with long-term reductions in pain and improved function in a real-world setting over 12 months ( P <0.01). Cryoneurolysis was relatively more effective compared with conventional intra-articular (IA) agents, most of which typically provide pain relief and functional improvement for 4-6 months. This data supports the use of cryoneurolysis for long-term pain management in patients with knee OA. Presenter: Mitchell K. Ng, MD Poster Number : e0233 Date & Time : March 2 nd , 2026, 7:00 AM CST About Pacira Pacira delivers innovative, non-opioid pain therapies to transform the lives of patients. Pacira has three commercial-stage non-opioid treatments: EXPAREL® (bupivacaine liposome injectable suspension), a long-acting local analgesic currently approved for infiltration, fascial plane block, and as an interscalene brachial plexus nerve block, an adductor canal nerve block, and a sciatic nerve block in the popliteal fossa for postsurgical pain management; ZILRETTA® (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular injection indicated for the management of osteoarthritis knee pain; and ioveraº, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. The company is also advancing a pipeline of clinical-stage assets for musculoskeletal pain and adjacencies, its most advanced product candidate, PCRX-201 (enekinragene inzadenovec), a novel locally administered gene therapy, is in Phase 2 clinical development for OA of the knee. To learn more about Pacira, visit . About EXPAREL® (bupivacaine liposome injectable suspension) EXPAREL is indicated to produce postsurgical local analgesia via infiltration in patients aged 6 years and older, and postsurgical regional analgesia via an interscalene brachial plexus block in adults, a sciatic nerve block in the popliteal fossa in adults, and an adductor canal block in adults. The safety and effectiveness of EXPAREL have not been established to produce postsurgical regional analgesia via other nerve blocks besides an interscalene brachial plexus nerve block, a sciatic nerve block in the popliteal fossa, or an adductor canal block. The product combines bupivacaine with multivesicular liposomes, a proven product delivery technology that delivers medication over a desired time period. EXPAREL represents the first and only multivesicular liposome local anesthetic that can be utilized in the peri- or postsurgical setting. By utilizing the multivesicular liposome platform, a single dose of EXPAREL delivers bupivacaine over time, providing significant reductions in cumulative pain scores with up to a 78 percent decrease in opioid consumption; the clinical benefit of the opioid reduction was not demonstrated. Additional information is available at Important Safety Information about EXPAREL for Patients EXPAREL should not be used in obstetrical paracervical block anesthesia. In studies in adults where EXPAREL was injected into a wound, the most common side effects were nausea, constipation, and vomiting. In studies in adults where EXPAREL was injected near a nerve, the most common side effects were nausea, fever, and constipation. In the study where EXPAREL was given to children, the most common side effects were nausea, vomiting, constipation, low blood pressure, low number of red blood cells, muscle twitching, blurred vision, itching, and rapid heartbeat. EXPAREL can cause a temporary loss of feeling and/or loss of muscle movement. How much and how long the loss of feeling and/or muscle movement depends on where and how much of EXPAREL was injected and may last for up to 5 days. EXPAREL is not recommended to be used in patients younger than 6 years old for injection into the wound, for patients younger than 18 years old, for injection near a nerve, and/or in pregnant women. Tell your health care provider if you or your child has liver disease, since this may affect how the active ingredient (bupivacaine) in EXPAREL is eliminated from the body. EXPAREL should not be injected into the spine, joints, or veins. The active ingredient in EXPAREL can affect the nervous system and the cardiovascular system; may cause an allergic reaction; may cause damage if injected into the joints; and can cause a rare blood disorder. About iovera ® ° The iovera° system uses the body’s natural response to cold to treat peripheral nerves and immediately reduce pain without the use of drugs. Treated nerves are temporarily stopped from sending pain signals for a period of time, followed by a restoration of function. Treatment with iovera° works by applying targeted cold to a peripheral nerve. A precise cold zone is formed under the skin that is cold enough to immediately prevent the nerve from sending pain signals without causing damage to surrounding structures. The effect on the nerve is temporary, providing pain relief until the nerve regenerates and function is restored. Treatment with iovera° does not include injection of any substance, opioid, or any other drug. The effect is immediate and can last up to 90 days. The iovera° system is not indicated for treatment of central nervous system tissue. Additional information is available at . Indication and Select Important Safety Information for iovera° Indication: iovera° applies freezing cold to peripheral nerve tissue to block and/or relieve pain for up to 90 days. It should not be used to treat central nervous system tissue. Important Safety Information Do not receive treatment with iovera° if you experience hypersensitivity to cold or have open and/or infected wounds near the treatment site. You may experience bruising, swelling, inflammation and/or redness, local pain and/or tenderness, and altered feeling at the site of application. In treatment area(s), you may experience damage to the skin, skin darkening or lightening, and dimples in the skin. You may experience a temporary loss of your ability to use your muscles normally outside of the treatment area. Talk to your doctor before receiving treatment with iovera°. About IGOR IGOR is a multi-center, multi-treatment, multi-outcome long-term registry that has the potential to provide valuable insights into safety, clinical effectiveness, patient response and economic outcomes of various treatment methods over time in real world practice. These insights can provide valuable information to help guide best practices for current surgical and non-surgical treatments of knee osteoarthritis, as well as inform the development of future therapies by providing a better understanding of patient characteristics and treatment response. Recognizing that osteoarthritis management spans multiple treatment paradigms, the IGOR registry was designed and is being conducted in collaboration with a multi-disciplinary team of specialists in orthopedic surgery, sports medicine, physiatry, rheumatology and family medicine. The robust design of IGOR is intended to capture real-world data across a broad range of osteoarthritis treatments, reflecting each patient’s dynamic care journey over an extended period. The study collects robust patient characteristics, as well as clinical, economic and patient-reported outcomes, with most patients contributing data over several years across multiple interventions. Much of this outcomes data is gathered directly from representative patients and clinical settings, with long-term engagement contributing to high quality, meaningful insights. Forward-Looking Statements Any statements in this press release about Pacira’s future expectations, plans, trends, outlook, projections and prospects, and other statements containing the words “believes,” “anticipates,” “plans,” “estimates,” “expects,” “intends,” “may,” “will,” “would,” “could,” “can” and similar expressions, constitute forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the Private Securities Litigation Reform Act of 1995, including, without limitation, statements related to: the contributions of new directors; '5x30', our growth and business strategy, our future outlook, the strength and efficacy of our intellectual property protection and patent terms, our future growth potential and future financial and operating results and trends, our plans, objectives, expectations (financial or otherwise) and intentions, including our plans with respect to the repayment of our indebtedness, anticipated product portfolio and product development programs, strategic alliances, plans with respect to the Non-Opioids Prevent Addiction in the Nation (“NOPAIN”) Act and any other statements that are not historical facts. For this purpose, any statement that is not a statement of historical fact should be considered a forward-looking statement. We cannot assure you that our estimates, assumptions and expectations will prove to have been correct. Actual results may differ materially from these indicated by such forward-looking statements as a result of various important factors, including risks relating to, among others: risks associated with acquisitions, such as the risk that the acquired businesses and/or assets will not be integrated successfully, that such integration may be more difficult, time-consuming or costly than expected or that the expected benefits of the transaction will not occur; our manufacturing and supply chain, global and United States economic conditions (including tariffs, inflation and rising interest rates), and our business, including our revenues, financial condition, cash flows and results of operations; the success of our sales and manufacturing efforts in support of the commercialization of EXPAREL, ZILRETTA and iovera°; the rate and degree of market acceptance of EXPAREL, ZILRETTA and iovera°; the size and growth of the potential markets for EXPAREL, ZILRETTA and iovera° and our ability to serve those markets; our plans to expand the use of EXPAREL, ZILRETTA and iovera° to additional indications and opportunities, and the timing and success of any related clinical trials for EXPAREL, ZILRETTA, iovera° and any of our other product candidates, including but not limited to PCRX-201; the commercial success of EXPAREL, ZILRETTA and iovera°; the related timing and success of United States Food and Drug Administration supplemental New Drug Applications and premarket notification 510(k)s; the related timing and success of European Medicines Agency Marketing Authorization Applications; our plans to evaluate, develop and pursue additional product candidates utilizing our proprietary multivesicular liposome (“pMVL”) drug delivery technology or our proprietary high-capacity adenovirus (“HCAd”) vector platform; the approval of the commercialization of our products in other jurisdictions (by either us or our partners); clinical trials in support of an existing or potential pMVL- or HCAd-based product; our commercialization and marketing capabilities; our ability to successfully complete capital projects; the outcome of any litigation; the recoverability of our deferred tax assets; assumptions associated with contingent consideration payments; assumptions used for estimated future cash flows associated with determining the fair value of the company; the anticipated funding or benefits of our share repurchase program; and factors discussed in the “Risk Factors” of our most recent Annual Report on Form 10-K and in other filings that we periodically make with the Securities and Exchange Commission (the “SEC”). In addition, the forward-looking statements included in this press release represent our views as of the date of this press release. Important factors could cause actual results to differ materially from those indicated or implied by forward-looking statements, and as such we anticipate that subsequent events and developments will cause our views to change. Except as required by applicable law, we undertake no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, and readers should not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from those expressed or implied by these statements. These factors include the matters discussed and referenced in the “Risk Factors” of our most recent Annual Report on Form 10-K and in other filings that we periodically make with the SEC. CONTACT: Investor Contact: Susan Mesco, (973) 451-4030 susan.mesco@pacira.com Media Contact: Sara Marino, (973) 248-7005 sara.marino@pacira.com